Canada's Valeant said it remained committed to
getting the deal done but would remain "financially disciplined."
Allergan, which makes the popular anti-wrinkle treatment Botox, said
on Monday that Valeant's business model was unsustainable and the
offer was too risky because of uncertainty about the company's
(Reporting by Esha Dey in Bangalore; Editing by Saumyadeb
[to top of second column]
[© 2014 Thomson Reuters. All rights
Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.